Prosecution Insights
Last updated: November 04, 2026

Mabwell (Shanghai) Bioscience Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days

Analysis

Mabwell (Shanghai) Bioscience Co. Ltd. manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. The busiest examiner for the company is WITHERSPOON, SIKARL A, who is responsible for 1 pending office action. This distribution means that each of the 2 pending actions is being reviewed by a different examiner in a different art unit.

Because there is no overlap between the 2 examiners or the 2 art units, the company cannot rely on a single unified strategy for its current pending matters. Each case must be handled according to the specific tendencies of the individual examiner and the standards of the respective art unit within the Biotechnology & Pharmaceuticals field. This fragmentation suggests that the 2 pending actions may cover diverse technical aspects of the company's technology. Practitioners should monitor the feedback from both examiners to identify any potential conflicts in claim scope or interpretation across the portfolio. The outcome of these 2 pending office actions will provide a baseline for future filings in these specific art units.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
2
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (50%)
Multi-statute (no §101)1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WITHERSPOON, SIKARL A 1 86.3% -20.1%
DONOGHUE, BRITTNEY ERIN 1 59.0% +47.6%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18682062 METHOD FOR SYNTHESIZING 5,8-DIAMINO-3,4-DIHYDRO-2H-1-NAPHTHALENONE AND INTERMEDIATE COMPOUND USED THEREIN WITHERSPOON, SIKARL A —
18557917 ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF DONOGHUE, BRITTNEY ERIN —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18557917 ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF DONOGHUE, BRITTNEY ERIN —

Top Art Units

Art UnitApps
1692 1
1675 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18682062 METHOD FOR SYNTHESIZING 5,8-DIAMINO-3,4-DIHYDRO-2H-1-NAPHTHALENONE AND INTERMEDIATE COMPOUND USED THEREIN WITHERSPOON, SIKARL A 1692 §101§112 Non-Final OA — Pending Feb 07, 2024
18557917 ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF DONOGHUE, BRITTNEY ERIN 1675 §102§103§112Other Non-Final OA — Pending Oct 27, 2023

Managing Mabwell (Shanghai) Bioscience Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Mabwell (Shanghai) Bioscience Co. Ltd. have?

Mabwell (Shanghai) Bioscience Co. Ltd. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Mabwell (Shanghai) Bioscience Co. Ltd. applications?

Sikarl A Witherspoon has the most, with 1 of Mabwell (Shanghai) Bioscience Co. Ltd.'s pending office actions.

What technology area are Mabwell (Shanghai) Bioscience Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month